

Yao-Tseng Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12032469/publications.pdf>

Version: 2024-02-01

119
papers

15,401
citations

36203

51
h-index

27345

106
g-index

122
all docs

122
docs citations

122
times ranked

14737
citing authors

#	ARTICLE	IF	CITATIONS
1	Minocycline-induced black bone disease with synovial pigmentation in a patient undergoing revision anterior cruciate ligament surgery: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 81, 105819.	0.2	1
2	High Interobserver Variability and Frequent Overdiagnosis of Dysplasia in Fundic Gland Polyps can be Improved by Detecting Atypia on Surface Epithelium and An Abrupt Transition to Non-Neoplastic Cells. <i>Histopathology</i> , 2021, .	1.6	0
3	High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. <i>Cancer Letters</i> , 2021, 514, 79-89.	3.2	14
4	RHAMMB-mediated bifunctional nanotherapy targeting Bcl-xL and mitochondria for pancreatic neuroendocrine tumor treatment. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 277-287.	2.0	5
5	Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 453-459.	0.6	12
6	Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. <i>NAR Cancer</i> , 2020, 2, zcaa009.	1.6	11
7	Classifying Lung Neuroendocrine Neoplasms through MicroRNA Sequence Data Mining. <i>Cancers</i> , 2020, 12, 2653.	1.7	11
8	Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. <i>Endocrine-Related Cancer</i> , 2019, 26, 47-57.	1.6	39
9	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 221-229.	1.3	27
10	Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. <i>Modern Pathology</i> , 2018, 31, 1756-1766.	2.9	33
11	Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. <i>Oncotarget</i> , 2018, 9, 20941-20952.	0.8	29
12	Bcl-xL promotes metastasis independent of its anti-apoptotic activity. <i>Nature Communications</i> , 2016, 7, 10384.	5.8	68
13	Cancer testis antigen expression in testicular germ cell tumors and in intratubular germ cell neoplasia. <i>Modern Pathology</i> , 2015, 28, 742-744.	2.9	2
14	A cautionary note on the immunohistochemical detection of braf v600e mutations in serrated lesions of the colon. <i>Modern Pathology</i> , 2015, 28, 740-741.	2.9	3
15	Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice. <i>Oncol Immunology</i> , 2014, 3, e28132.	2.1	4
16	Cancer-Testis Antigen Expression in Digestive Tract Carcinomas: Frequent Expression in Esophageal Squamous Cell Carcinoma and Its Precursor Lesions. <i>Cancer Immunology Research</i> , 2014, 2, 480-486.	1.6	31
17	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
18	Expression of cancer/testis (CT) antigens in squamous cell carcinoma of the head and neck: Evaluation as markers of squamous dysplasia. <i>Pathology Research and Practice</i> , 2013, 209, 721-726.	1.0	17

#	ARTICLE	IF	CITATIONS
19	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	1.1	31
20	Effects of CT-Xp Gene Knock down in Melanoma Cell Lines. <i>Oncotarget</i> , 2013, 4, 531-541.	0.8	23
21	Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas. <i>Cancer Immunity</i> , 2013, 13, 10.	3.2	3
22	Colon cancer associated transcript α 1: A novel RNA expressed in malignant and pre-malignant human tissues. <i>International Journal of Cancer</i> , 2012, 130, 1598-1606.	2.3	250
23	Cancer/Testis Antigens: Potential Targets for Immunotherapy. , 2012, , 347-369.		10
24	NY-ESO-1 as a predictive and prognostic marker in NSCLC.. <i>Journal of Clinical Oncology</i> , 2012, 30, e17539-e17539.	0.8	0
25	The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens. <i>Cancer Immunity</i> , 2012, 12, 8.	3.2	3
26	Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e17876.	1.1	84
27	Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. <i>Human Reproduction</i> , 2011, 26, 3232-3243.	0.4	37
28	Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3093-3098.	3.3	35
29	Seromic profiling of ovarian and pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5088-5093.	3.3	163
30	CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. <i>Nucleic Acids Research</i> , 2009, 37, D816-D819.	6.5	338
31	CT-X antigen expression in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13493-13498.	3.3	92
32	Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. <i>International Journal of Cancer</i> , 2009, 124, 2893-2898.	2.3	53
33	Identification of borderline thyroid tumors by gene expression array analysis. <i>Cancer</i> , 2009, 115, 5421-5431.	2.0	40
34	Cancer/testis (CT) antigens: Potential targets for immunotherapy. <i>Cancer Science</i> , 2009, 100, 2014-2021.	1.7	478
35	Autoantibodies Against Cancer Antigens. <i>Methods in Molecular Biology</i> , 2009, 520, 11-19.	0.4	45
36	Clinical, Pathologic, and Molecular Features of Early-onset Colorectal Carcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 572-582.	2.1	152

#	ARTICLE	IF	CITATIONS
37	Distinct expression patterns of the immunogenic differentiation antigen NY-ESO-1 in normal breast, testis and their malignant counterparts. <i>International Journal of Cancer</i> , 2008, 122, 1585-1591.	2.3	20
38	MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. <i>Modern Pathology</i> , 2008, 21, 1139-1146.	2.9	195
39	Genome-wide analysis of cancer/testis gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20422-20427.	3.3	295
40	ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3291-3298.	3.2	32
41	Survivin as a Useful Adjunct Marker for the Grading of Papillary Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 224-231.	1.2	18
42	NY-BR-1 is a Differentiation Antigen of the Mammary Gland. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 77-83.	0.6	33
43	NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. <i>International Journal of Cancer</i> , 2007, 120, 2411-2417.	2.3	65
44	Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. <i>Modern Pathology</i> , 2007, 20, 921-928.	2.9	155
45	Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1183-1192.	2.0	8
46	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1723-1731.	2.0	55
47	PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. <i>Cancer Immunity</i> , 2007, 7, 18.	3.2	51
48	NY-ESO-1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	1.9	311
49	Microarray Analysis of Thyroid Nodule Fine-Needle Aspirates Accurately Classifies Benign and Malignant Lesions. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 490-498.	1.2	57
50	Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1281-1285.	1.4	31
51	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 56, 249-258.	2.0	17
52	Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 392-400.	1.5	34
53	Diagnostic Usefulness of HBME1, Galectin-3, CK19, and CITED1 and Evaluation of Their Expression in Encapsulated Lesions With Questionable Features of Papillary Thyroid Carcinoma. <i>American Journal of Clinical Pathology</i> , 2006, 126, 700-708.	0.4	128
54	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 2745-2751.	3.2	42

#	ARTICLE	IF	CITATIONS
55	Gene Expression Profiling Separates Chromophobe Renal Cell Carcinoma from Oncocytoma and Identifies Vesicular Transport and Cell Junction Proteins as Differentially Expressed Genes. <i>Clinical Cancer Research</i> , 2006, 12, 6937-6945.	3.2	79
56	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , 2006, 108, 3492-3492.	0.6	1
57	The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. <i>Blood</i> , 2005, 106, 167-174.	0.6	172
58	Identification of cancer/testis-antigen genes by massively parallel signature sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7940-7945.	3.3	109
59	Cancer/testis antigens, gametogenesis and cancer. <i>Nature Reviews Cancer</i> , 2005, 5, 615-625.	12.8	1,415
60	Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. <i>Cancer</i> , 2005, 103, 2575-2583.	2.0	72
61	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18538-18543.	3.3	2,100
62	CD4+ T Cell Responses to SSX-4 in Melanoma Patients. <i>Journal of Immunology</i> , 2005, 174, 5092-5099.	0.4	20
63	Messenger RNA Expression Ratios among Four Genes Predict Subtypes of Renal Cell Carcinoma and Distinguish Oncocytoma from Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 6558-6566.	3.2	42
64	Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. <i>International Journal of Oncology</i> , 2005, 26, 57.	1.4	1
65	Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. <i>Clinical Immunology</i> , 2005, 114, 70-78.	1.4	17
66	CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.. <i>Blood</i> , 2005, 106, 356-356.	0.6	6
67	Identification of CT46/HORMAD1, an immunogenic cancer/testis antigen encoding a putative meiosis-related protein. <i>Cancer Immunity</i> , 2005, 5, 9.	3.2	56
68	Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. <i>Cancer Immunity</i> , 2005, 5, 11.	3.2	39
69	NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6551-6558.	3.2	62
70	NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. <i>Cancer Research</i> , 2004, 64, 2199-2204.	0.4	92
71	Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1. <i>Clinical Cancer Research</i> , 2004, 10, 8396-8404.	3.2	55
72	Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients. <i>Journal of Immunology</i> , 2004, 172, 3289-3296.	0.4	176

#	ARTICLE	IF	CITATIONS
73	Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells. <i>Journal of Immunology</i> , 2004, 172, 7206-7211.	0.4	17
74	IFN- γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14467-14472.	3.3	36
75	Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10697-10702.	3.3	411
76	Real-Time, label-free monitoring of tumor antigen and serum antibody interactions. <i>Journal of Proteomics</i> , 2004, 61, 283-298.	2.4	78
77	Expression of cancer/testis (CT) antigens in lung cancer. <i>Lung Cancer</i> , 2003, 42, 23-33.	0.9	123
78	Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression. <i>Genomics</i> , 2003, 82, 628-636.	1.3	22
79	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8862-8867.	3.3	179
80	Immunomic analysis of human sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2651-2656.	3.3	98
81	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. <i>Journal of Immunology</i> , 2003, 170, 1191-1196.	0.4	50
82	NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. <i>Cancer Research</i> , 2003, 63, 6076-83.	0.4	191
83	SSX antigens as tumor vaccine targets in human sarcoma. <i>Cancer Immunity</i> , 2003, 3, 13.	3.2	13
84	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11813-11818.	3.3	83
85	A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. <i>Gene</i> , 2002, 297, 141-149.	1.0	26
86	Identification of cancer/testis genes by database mining and mRNA expression analysis. <i>International Journal of Cancer</i> , 2002, 98, 485-492.	2.3	111
87	CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. <i>International Journal of Cancer</i> , 2002, 99, 839-845.	2.3	60
88	The SSX gene family: Characterization of 9 complete genes. <i>International Journal of Cancer</i> , 2002, 101, 448-453.	2.3	106
89	Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. <i>Immunological Reviews</i> , 2002, 188, 22-32.	2.8	739
90	Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. <i>Cancer Research</i> , 2002, 62, 4041-7.	0.4	149

#	ARTICLE	IF	CITATIONS
91	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. <i>Cancer Immunity</i> , 2002, 2, 12.	3.2	14
92	Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2001, 9, 29-34.	0.6	0
93	Immunohistochemical and Reverse Transcription-Polymerase Chain Reaction Expression Analysis of Tyrosinase and Microphthalmia-Associated Transcription Factor in Angiomyolipomas. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2001, 9, 29-34.	2.0	15
94	Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. <i>International Journal of Cancer</i> , 2001, 92, 856-860.	2.3	310
95	Expression of MAGE-antigens in normal tissues and cancer. <i>International Journal of Cancer</i> , 2000, 85, 460-465.	2.3	179
96	CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. , 2000, 85, 726-732.		105
97	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. <i>Journal of Immunology</i> , 2000, 165, 948-955.	0.4	161
98	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1-Expressing Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 191, 625-630.	4.2	196
99	T311 An Anti-Tyrosinase Monoclonal Antibody for the Detection of Melanocytic Lesions in Paraffin Embedded Tissues. <i>Pathology Research and Practice</i> , 2000, 196, 235-242.	1.0	73
100	Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. <i>Cancer Letters</i> , 2000, 150, 155-164.	3.2	117
101	SEREX analysis of gastric cancer antigens. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, S37-S42.	1.1	18
102	Expression of MAGE-antigens in normal tissues and cancer. , 2000, 85, 460.		1
103	Identification of cancer antigens in breast cancer by the SEREX expression cloning method. <i>Breast Cancer</i> , 1999, 6, 305-311.	1.3	28
104	Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 434, 429-435.	1.4	48
105	Isoforms of the human PDZ-73 protein exhibit differential tissue expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1445, 39-52.	2.4	37
106	Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. , 1999, 84, 506-510.		194
107	Antigens recognized by autologous antibody in patients with renal-cell carcinoma. , 1999, 83, 456-464.		146
108	Characterization of human colon cancer antigens recognized by autologous antibodies. , 1998, 76, 652-658.		281

#	ARTICLE	IF	CITATIONS
109	Expression of SSX genes in human tumors. , 1998, 77, 19-23.		143
110	Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. , 1998, 78, 387-389.		99
111	A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. Journal of Experimental Medicine, 1998, 187, 1349-1354.	4.2	642
112	New Paths in Human Cancer Serology. Journal of Experimental Medicine, 1998, 187, 1163-1167.	4.2	433
113	Simultaneous Humoral and Cellular Immune Response against Cancerâ€™Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2â€™binding Peptide Epitopes. Journal of Experimental Medicine, 1998, 187, 265-270.	4.2	668
114	Characterization of human colon cancer antigens recognized by autologous antibodies. , 1998, 76, 652.		1
115	A103. American Journal of Surgical Pathology, 1998, 22, 595-602.	2.1	233
116	Expression of Melan-A (MART1) in Benign Melanocytic Nevi and Primary Cutaneous Malignant Melanoma. American Journal of Surgical Pathology, 1998, 22, 976-982.	2.1	227
117	MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. , 1997, 33, 233-239.		85
118	SSX: A multigene family with several members transcribed in normal testis and human cancer. , 1997, 72, 965-971.		190
119	Tla-region genes and their products. Immunologic Research, 1987, 6, 30-45.	1.3	33